Drug profile

The FDA adverse-event record for Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage)

89 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage). See the species affected, top reactions, and outcomes below.

89
adverse-event reports
97.8%
death-coded share
Fish
most-reported species
63
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
89
Total Reports
87
Deaths Reported
97.8%
Death Rate

Active Ingredients

Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage)

Administration Routes

Unknown

Species Affected

Fish 88
Unknown 1

Most Affected Breeds

Atlantic Salmon (Salmo salar) 88
Unknown 1

Most Reported Reactions

Death 63
IGA Animal mortality greater than expected 35
Fish body deformity 28
Moribund 24
IGA Animal morbidity greater than expected 17
Death by euthanasia 14
Partial lack of efficacy 2
Product Defect, General 2
Genotypic test failure (IGA) 2
Unrelated death 1
Fungal skin infection NOS 1
Containment system or component failure (IGA) 1

Outcome Breakdown

Died
63 (59.4%)
Euthanized
39 (36.8%)
Ongoing
4 (3.8%)

Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) Adverse Event Insights

89 reports name Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage); 87 recorded a death outcome (97.8% of reported events, not a population-level mortality rate). Active ingredient: Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage). Administration route: Unknown.

By species: Fish (88 reports), Unknown (1 reports). By breed: Atlantic Salmon (Salmo salar) (88), Unknown (1).

Leading clinical signs: Death (63), IGA Animal mortality greater than expected (35), Fish body deformity (28), Moribund (24). Outcome, 106 coded reports: Died leads at 59.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.